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3 reasons. 1) To elucidate the relation between Pfs48/45 and the Pfs230 and 2) to measure and characterize anti-Pfs48/45 antibodies in experimental and field sera.
Phage display antibodies offer a method for the production of high affinity single chain variable fragment (ScFv) derivatives of human antibodies of "natural host" origin [for reviews, see 7] . Our objective is to produce human mAbs against Pfs48/45, a sexual stage antigen of P. falciparum. For this study combinatorial phage display libraries were constructed using B -lymphocytes from P. falciparum gametocyte carriers with TB-immunity.
Subsequently, phages were selected from these libraries by panning on Pfs48/45 antigen and phages bound to the antigen eluted by competition with mAbs [8] . This resulted in human scFv antibodies directed against epitope III of Pfs48/45.
Materials and Methods

Parasites
Mature P. falciparum gametocytes (NF54 strain) were produced in a semi-automated system as described before [12] . Gametocytes were isolated as previously described [13] . The purified gametocytes were used a) directly, in immunofluorescence assays (see below), or b) stored at -70 0 C until used.
Gametocyte antigens were extracted using 25 mM Tris-HCl (pH 8.0) supplemented with 150 mM NaCl, 1.0% Nonidet P40 (NP40), 1 mM phenylmethylsulphonyl fluoride and 1 µg/ml each of DNase and RNase. Insoluble debris was pelleted by centrifugation (16,000g, 5 min at room temperature) and the supernatant was stored at -20 0 C until used for Westernblot analysis, for immobilization of Pfs48/45 in the phage selection procedure or in ELISA's.
Monoclonal antibodies (mAbs)
Anti-Pfs48/45 murine mAbs 32F3 (IgG1; epitope Ia) and 32F1 (IgG2a; epitope IIb) and rat mAbs 85RF45.1, 85RF45.2b, 85RF45.3 and 85RF45.5 (recognizing epitope I, IIb, III and V of Pfs48/45) have been described previously [3, 6] . MAb P5D4 recognizes the C -terminal vesicular stomatitis virus glycoprotein (VSV-G) [14] . Labeling of mAb P5D4 with horseradish peroxidase (HRPO) was performed using the periodate method with a molar input HRPO/IgG ratio of 4 [15] . The labeled mAb was dialyzed against PBS, supplemented with thimerosal (0.01%) and FCS (1%) and stored at -20°C.
Phage libraries and selection procedures
In this study, two human phage display combinatorial immune antibody libraries were used.
The scFv library was derived from RNA obtained from lymphocytes of a) 10 gametocyte carriers from Cameroon after pooling of the lymphocytes (Cam; 80x10 6 cells) and b) a Dutch expatriate (Spa; 45x10 6 cells) living in Cameroon for more than thirty years with regular attacks of clinical malaria. The scFv library was made essentially as described by Marks et al., [16] and Hoet et al., [9] .
We used a two step cloning procedure whereby the heavy and light chain repertoires were sequentially cloned in the phagemid vector pHENIX containing the VSV-G tag [14, Raats et al.,
unpublished results]. Library diversity was analyzed by PCR and fingerprinting (Bst NI digestion).
The phage libraries were panned for binders using immunotubes (Nunc, Maxisorp) coated with a NP40 extract of gametocytes (500,000 parasite equivalents/tube). Elution of antigen binding clones was performed by competition with a mixture of 4 rat mAbs (concentration of 60ug/ml each) (recognizing epitope I, IIb, III and V of Pfs48/45) for 90 min. The eluted phages were then allowed to infect E.coli TG1 host cells to amplify selected phage binding to Pfs48/45.
After amplification phages were selected for two additional rounds using the same protocol. An aliquot of the polyclonal phages obtained after each round of selection was stored at 4°C until required.
After each round of selection, 96 single clones were screened for binding to Pfs48/45 by ELISA. Clones of interest were characterized by: a) PCR-fingerprinting using the restriction 
ELISA screening
Pfs48/45 specific ELISA was performed by a two-site ELISA as previously described [10] . Briefly, microtiter plates were coated with 50 µl of anti-Pfs48/45 mouse mAbs recognizing different epitopes (10 µg/ml) in PBS for 30 minutes. After washing and incubation with parasite extract (200,000 parasite equivalents/well), 50ul bacterial culture supernatant containing scFv or phage antibodies were applied. Bound scFvs were detected by HRPOlabeled mouse mAb P5D4 and bound phages by HRPO-labeled anti-M13 mouse mAb using 3,3',5,5'-tetra-methyl-benzidine (TMB, Sigma). Adding H2SO4 after 20 min stopped the reaction and the optical density (OD) was measured at 450 nm (Titertek Multiskan MCC/340).
Epitope recognition of Pfs48/45 by phage or soluble scFv was carried out by a competition ELISA as previously described [10] . Briefly, Pfs48/45 was captured from antigen extract in microtiter plates. After washes with PBS, wells were incubated with a mixture of 30 µl test sample and 30 µl HRPO-labeled anti-Pfs48/45 mAb (recognizing various epitopes of Pfs48/45) for 120 min and detected using TMB as described above. 
Blotting procedures
For an indication of scFv expression levels in bacterial culture supernatants, nitrocellulose filters were placed in a dot-blotting apparatus (Schleicher & Schull), and bacterial culture supernatant was applied. Filters were dried and blocked with MPBS for 20 min, bound scFv was detected using anti-VSV and alkaline-phosphatase-conjugated rabbit antimouse (Dakopatts; 1:1,000 dilution). Dots were visualized using nitro blue tetrazolium/ bromochloroindolyl phosphate (NBT/BCIP). 
Results
Two combinatorial human scFv antibody libraries were constructed using B cells from P.falciparum gametocyte carriers essentially as described by Hoet et al., [9] . After a primary and a second amplification of heavy-and light chain genes using PCR and digestion of these products both V H and V L genes were purified by Wizard PCR prep (Promega) and sequentially ligated in the pHENIX vector. The diversity of the resulting libraries was over (Table 1 ). Library quality was analyzed by PCR for full-length inserts (>75%) and dot-blot analysis for percentage of clones producing soluble antibodies ( Table 1) .
The phage libraries were incubated with an NP40 extract of gametocytes immobilized to the wall of immunotubes. After washing, the bound phages were eluted by competition with a mixture of 4 rat monoclonal antibodies (mAbs) recognizing epitope I, IIb, III and V of Pfs48/45 at a concentration of 60µg/ml each. Displaced phages were used for infection of bacteria, grown, combined and subjected to further selection rounds (in total 3 rounds). After (data not shown).
9
Eleven clones selected from the 2 human libraries were further analyzed by sequence analysis ( Fig. 1 ) and grouped as depicted in Table 2 (Table 2) .
Six clones from the Spa-library and 2 clones of the Cam-library showed significant competition for epitope III of Pfs48/45 in the competition-ELISA whereas no competition was found for epitope I, IIb and V of Pfs48/45. All clones positive in the competition ELISA were positive for Pfs48/45 on the Western immunoblot (Fig. 2) . Clone SG10 has a weak reactivity in the competition ELISA and also a weak reactivity in the IFA ( Table 2 ). The competition-ELISA positive clones and the uniformity of the V H and V L genes encoding the different scFvs suggested that these clones were directed against the same or related epitopes of Pfs48/45. To explore this possibility, we produced scFv and phage antibodies from 11
clones to test the capacity of phages to replace scFvs after binding to Pfs48/45. The percentage inhibition of binding of scFvs to Pfs48/45 by phage antibodies of clone SB12 is depicted in Fig. 3 . The percentage inhibition of scFvs binding to Pfs48/45 by phage antibodies from clones KC4, SG3 and KH9 was comparable (data not shown). Phages of clone KC4 did only compete with bound scFv of KC4 and no competition was found with the other clones.
This was also seen for clone SG3 and KH9. The clones SB12 till SG10 showed competition suggested specificity for epitope III of Pfs48/45 whereas the clones for Pfs48/45 unrelated antigen did not compete. These results show that phage antibodies from the 8 competition-ELISA positive clones ( Table 2) were capable of inhibiting the interaction of scFv antibody fragments to Pfs48/45 for more than 65%. Collectively, these experiments support the notion that all clones are directed against the same or closely spaced epitopes.
The serum of the malaria patient from which the immune library (Spa) was constructed was tested for its ability to compete with anti-Pfs48/45 antibody fragments for binding to Pfs48/45 in comparison with a blood bank donor serum. The patient serum was able to inhibit the binding of scFvs from clones KG2, SB12 and SF5 to Pfs48/45 whereas the serum from the negative blood bank donor was unable to inhibit binding (Fig. 4) . The patient serum competes strongly with the 3 clones, starting inhibition at a reciprocal dilution of 320 for clone SF5, 640 for clone KG2 and 1,280 for clone SB12. The other clones (SF3, KB6, SF1 and SC8) gave comparable results (data not shown). Clone SG10, with the lowest competition titer for epitope III of Pfs48/45 (Table 2 ) started inhibition at a reciprocal dilution of 80.
Furthermore, 48 sera of gametocyte carriers were analyzed in the competition ELISA with mAb 85RF45.3 and scFv clone SB12 as competitor. Sixteen (33%) out of 48 gametocyte carriers were able to compete with both labels in the Pfs48/45 competition ELISA at dilutions varying from 1/20 to 1/640 (Table 3) . Five (10%) sera were positive with mAb 85RF45.3 as competitor but negatives with clone SB12 in the competition ELISA. The low titer sera (>1/160) seem to be lower with clone SB12 as competitor in comparison with the mAb 85RF45.3. These results imply that the antibody fragments selected from the two different libraries recognize similar epitope regions on Pfs48/45 as anti-Pfs48/45 antibodies present in malaria patients' sera.
Discussion
In the present study we have employed a novel strategy for generating recombinant human monoclonal antibody fragments from peripheral B cells from malaria immune patients.
Selection of recombinant human monoclonal antibody fragments specific for the Pfs48/45
antigen from phage display libraries was carried out successfully by competitive elution with mAbs specific for this antigen. This competitive elution technique between a mAb and phage antibody for binding an epitope is based on the principle of a Pfs48/45 two-site ELISA [10] .
The libraries from malaria patients used in this study had at least 10 E 8 independent clones with >75% full length insert ratios. Despite the mix of 4 mAbs (recognizing epitopes I, IIb, III and V), used for competitive elution, only phage antibodies directed to epitope III of Pfs48/45
were selected. However, the serum of the malaria patient of library SpA reacted with all epitopes of Pfs48/45 as measured by the competition ELISA with the anti-Pfs48/45 rat and mouse mAbs (data not shown). We have previously described [11] a fair agreement between TB-activity using a feeder assay with NF54 P.falciparum parasites and reactivity in Pfs48/45 competition-ELISA's using mouse mAbs in sera from gametocyte carriers from Cameroon. These data show that overall the C45-ELISA for epitope III is a good marker for the comparison with TB-activity in serum samples. Also, table 3 shows a good correlation between reactivity of scFv with the sera from gametocyte carriers in comparison with the rat mAb 85RF45.3. However, TBactivity was only found for mouse mAbs 82C4.A9 and 81D3.D2 (both epitope III specific and of IgM isotype) [5] . All other mouse and rat mAbs against epitope III of Pfs48/45 with IgG isotype show no TB-activity [5, 6] . In a pilot experiment, 4 scFv clones did not block the transmission of the parasite (data not shown). For comparison with the blocking mouse mAbs, it is better to make Fab-fragments, diabodies or tetrabodies. In further studies, the TBcapacity of the selected clones will be studied by making these fragments. Also different selection methods will be performed to get scFv fragments to other epitopes.
For Pfs48/45 vaccine development it is important to study anti Pfs48/45 antibody profiles in endemic sera after natural infections. So far, the possibility for such study was limited due to high background reactivity by using mouse and rat mAbs to capture antigen.
This problem could be partly resolved by using F(ab)2 fragments; however, different methods failed so far to produce and purify F(ab)2 fragments of these anti-Pfs48/45 mAbs. Since scFv fragments lack the cross reactive mouse and rat antibody domains we anticipated that high 13 background could be avoided. Preliminary data suggest that the background can be circumvented by these scFv preparations.
In conclusion, the successful selection of human scFv against Pfs48/45 paved the way for future selection of more recombinant antibodies with possible TB-activity. This would emphasize the importance of this molecule as vaccine candidate. Malaria patient-derived phage antibody display libraries can thus be used to isolate specific immunological reagents of human origin, useful in both the characterizations of the parasite's antigenic composition and the human hosts' immune response to malaria infection. Clones started with a S were selected from the Spa-library and started with K from the Camlibrary 18 
